Ridgetech Inc (Nasdaq:RDGT), a wholesale distributor of pharmaceutical and other healthcare products in China, on Friday reported its financial results for the fiscal year ended 31 March 2026.
Full-year revenue was USD132.16m, up 10.2% from USD119.97m in the same period of last year.
Gross profit increased 23.8% to USD4.75m, from USD3.84m a year ago.
Net loss was USD1.25m or USD17.21 per basic and diluted loss per share, compared to net income of USD10.20m or USD275.87 per basic and diluted earnings per share for the year-ago period.
Net loss from continuing operations was USD1.25m and USD1.45m in the years ended 31 March 2026 and 2025.
"Fiscal year 2026 marked a transformative year for Ridgetech as we completed our strategic transition to a wholesale-focused business model," said Frank Zhao, interim chief executive officer and chief financial officer. "Through the acquisition of Allright (Hangzhou) Internet Technology Co Ltd and the divestiture of our retail drugstore business, we have strengthened our position as an online and offline wholesale distributor of pharmaceutical and healthcare products, establishing a more scalable and efficient operating platform."
Valerio Therapeutics signs R&D collaboration with Abivax and outlines pipeline milestones
Labcorp declares quarterly dividend of USD0.72 per share
Aptamer Group launches Optimer-based Ebola diagnostic programme
SK bioscience to lead Gates Foundation-funded ROTOR project
Nona Biosciences and Lonza collaborate on antibody-based BBB-crossing technology for CNS diseases